Adaptive Biotechnologies Corporation $ADPT Shares Bought by Allianz Asset Management GmbH

Allianz Asset Management GmbH increased its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 305.8% during the third quarter, HoldingsChannel.com reports. The fund owned 321,774 shares of the company’s stock after buying an additional 242,474 shares during the period. Allianz Asset Management GmbH’s holdings in Adaptive Biotechnologies were worth $4,814,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in shares of Adaptive Biotechnologies in the second quarter valued at about $793,000. SG Americas Securities LLC lifted its position in shares of Adaptive Biotechnologies by 53.2% during the 2nd quarter. SG Americas Securities LLC now owns 37,328 shares of the company’s stock valued at $435,000 after acquiring an additional 12,963 shares during the period. Hillsdale Investment Management Inc. purchased a new stake in shares of Adaptive Biotechnologies during the 2nd quarter worth approximately $6,618,000. Envestnet Asset Management Inc. acquired a new position in Adaptive Biotechnologies during the second quarter worth $467,000. Finally, Intech Investment Management LLC increased its position in shares of Adaptive Biotechnologies by 26.0% in the second quarter. Intech Investment Management LLC now owns 72,605 shares of the company’s stock valued at $846,000 after buying an additional 14,990 shares in the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 34,668 shares of Adaptive Biotechnologies stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $18.60, for a total transaction of $644,824.80. Following the transaction, the insider directly owned 1,187,644 shares of the company’s stock, valued at $22,090,178.40. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Francis Lo sold 113,890 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $15.57, for a total transaction of $1,773,267.30. Following the completion of the sale, the insider directly owned 315,978 shares of the company’s stock, valued at $4,919,777.46. The trade was a 26.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 1,513,196 shares of company stock worth $26,291,033. Corporate insiders own 6.40% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on ADPT. Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a research note on Friday. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Morgan Stanley assumed coverage on Adaptive Biotechnologies in a research report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price objective on the stock. Finally, Guggenheim lifted their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.56.

Adaptive Biotechnologies Stock Down 1.4%

Shares of ADPT opened at $15.64 on Wednesday. Adaptive Biotechnologies Corporation has a fifty-two week low of $6.26 and a fifty-two week high of $20.76. The company’s fifty day moving average is $16.91 and its two-hundred day moving average is $15.33. The firm has a market cap of $2.39 billion, a PE ratio of -39.10 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. During the same period last year, the company posted ($0.23) EPS. The business’s quarterly revenue was up 51.0% on a year-over-year basis. As a group, equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.